Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fady Baselious

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Computers in Biology and Medicine|November 16, 2023
Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case studyFady Baselious, Dina Robaa, Wolfgang Sippl
Computers in Biology and Medicine|July 5, 2025
In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitorsFady Baselious, Sebastian Hilscher, Lukas Handke, et al.
International Journal of Molecular Sciences|January 27, 2024
Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 InhibitorFady Baselious, Sebastian Hilscher, Dina Robaa, et al.
Future Medicinal Chemistry|August 3, 2022
Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's diseaseAnsgar Opitz, Lisa-Marie Seitz, Vladimir Krystof, et al.
ACS Omega|November 3, 2025
Substrate-Guided Development of HDAC11-Selective Inhibitors Featuring α‑Amino Amide Zinc-Binding GroupsSebastian Hilscher, Marat Meleshin, Fady Baselious, et al.
Archiv Der Pharmazie|July 12, 2024
Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activityFady Baselious, Sebastian Hilscher, Sven Hagemann, et al.
Archiv Der Pharmazie|September 18, 2024
Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cellsFrancesco Berluti, Fady Baselious, Sven Hagemann, et al.
Drug Development Research|April 30, 2024
Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitorsDana M Odeh, Heba Abdelrasheed Allam, Fady Baselious, et al.
Bioorganic Chemistry|March 31, 2023
Arylidine extensions of 3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-benzenesulfonamide derivatives: Synthesis, computational simulations and biological evaluation as tumor-associated carbonic anhydrase inhibitorsHeba M Metwally, Heba Abdelrasheed Allam, Fady Baselious, et al.
Journal of Medicinal Chemistry|September 20, 2024
Development of Fragment-Based Inhibitors of the Bacterial Deacetylase LpxC with Low Nanomolar ActivitySebastian Mielniczuk, Katharina Hoff, Fady Baselious, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Computers in Biology and Medicine|November 16, 2023
Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case studyFady Baselious, Dina Robaa, Wolfgang Sippl
Computers in Biology and Medicine|July 5, 2025
In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitorsFady Baselious, Sebastian Hilscher, Lukas Handke, et al.
International Journal of Molecular Sciences|January 27, 2024
Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 InhibitorFady Baselious, Sebastian Hilscher, Dina Robaa, et al.
Future Medicinal Chemistry|August 3, 2022
Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's diseaseAnsgar Opitz, Lisa-Marie Seitz, Vladimir Krystof, et al.
ACS Omega|November 3, 2025
Substrate-Guided Development of HDAC11-Selective Inhibitors Featuring α‑Amino Amide Zinc-Binding GroupsSebastian Hilscher, Marat Meleshin, Fady Baselious, et al.
Archiv Der Pharmazie|July 12, 2024
Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activityFady Baselious, Sebastian Hilscher, Sven Hagemann, et al.
Archiv Der Pharmazie|September 18, 2024
Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cellsFrancesco Berluti, Fady Baselious, Sven Hagemann, et al.
Drug Development Research|April 30, 2024
Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitorsDana M Odeh, Heba Abdelrasheed Allam, Fady Baselious, et al.
Bioorganic Chemistry|March 31, 2023
Arylidine extensions of 3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-benzenesulfonamide derivatives: Synthesis, computational simulations and biological evaluation as tumor-associated carbonic anhydrase inhibitorsHeba M Metwally, Heba Abdelrasheed Allam, Fady Baselious, et al.
Journal of Medicinal Chemistry|September 20, 2024
Development of Fragment-Based Inhibitors of the Bacterial Deacetylase LpxC with Low Nanomolar ActivitySebastian Mielniczuk, Katharina Hoff, Fady Baselious, et al.
Pageof 2